New crown drug: Redsiway 2020 sales expected to exceed $2.8 billion...

Best-selling global new crown drug 1. Redsivir: At the start of the new crown outbreak, which was expected to sell more than $2.8 billion in 2020, Gilead's original drug for the Ebola virus, Veklury (Remdesivir), was considered one of the special drugs expected to be used to treat the new crown, as a broad-spectrum antirnavirus drug, which at the time was also known to the public as "the hope of the people".
, Redsyvir became the first drug to be conditionly approved in Japan, Europe and the United States to fight new coronary pneumonia.
May 2020, Gilead Sciences announced that Japan's Ministry of Health, Labour and Co., D.C., had approved Redsyvir as a treatment for SARS-CoV-2 infection through special approval.
's special approval was granted due to the pandemic of new coronavirus pneumonia, which refers to Redsiway's emergency use authorization in the United States, and in July 2020, the European Union officially approved Redsyvir's listing as the first drug licensed at the EU level to treat new coronary pneumonia.
The European Medicines Agency recommends the use of Redsyvir for patients with severe neocytosis who require oxygen treatment and are 12 years of age and older, and is limited to medical facilities to monitor patients at all time;
approval is based on the final results of three randomized controlled trials, including the recently published national Institute of Allergy and Infectious Diseases double-blind placebo-controlled Phase 3 ACTT-1 trial.
However, 2020 has also been a controversial year for Redsiway, with the WHO releasing dynamic updated guidelines for the treatment of new coronary pneumonia, focusing on Redsyvir, which does not recommend the use of Redsyvir in hospital patients regardless of the severity of the condition, with a recommended strength rating of weak or conditional; However, despite the controversial efficacy of the drug, there is still a clinical demand for Redsyvir in the global pandemic, and there is even a shortage of supply.
Gilead reported sales of $785 million in the U.S., $0.6 billion in the European Union in the first three quarters, $228 million in other markets and nearly 90 percent of global sales in the U.S.
expects Redsiver's 2020 sales to be between $2.825 billion and $2.825 billion.
agency forecasts that the drug's peak sales will be $3,074 million in 2021, after which sales will fall to $1,729 million in 2026.
2. Lianhua Qing Plague: Annual sales are expected to break 4 billion yuan Lianhua Qing Plague Capsules is a new Chinese medicine developed by Ling Pharmaceuticals during the "SARS" period in 2003, approved in April 2020 for the routine treatment of neo-crown pneumonia.
its efficacy mainly has the effect of detoxifying the plague, venting the lung fever, mainly used for the treatment of influenza is a hot poison attack lung certificate.
2020, the brand awareness of Lianhua Qing plague products has increased significantly, the domestic market demand has increased significantly, and more than 10 registered overseas countries to achieve sales.
2019, the company achieved operating income of 1.703 billion yuan, accounting for 29.24% of the company's total operating income.
January 3, 2020 results were announced by Ling Pharmaceuticals: Net income attributable to shareholders of listed companies is expected to be RMB1,152 million-RMB1.274 billion for the full year of 2020, up 90%-110% YoY, with underlying earnings per share expected to be RMB0.97/share-1.07 yuan/share.
the reasons for the change in performance, Ering Pharmaceuticals said, on the one hand, Lianhua Qing plague product sales revenue achieved rapid growth compared to the same period last year, on the other hand, the sales revenue of cardiovascular products achieved year-on-year growth.
data show that Lianhua Qing plague 2020H1 sales of about 2,024 million yuan, up 137% YoY, Q3 sales of about 850 million yuan, an increase of more than 50% YoY.
with the arrival of the autumn and winter festival, respiratory disease medication into the sales season, it is expected that the Q4 even flower plague growth will still be considerable.
analysts also pointed out that in the first three quarters of 2020, Lianhua Qing plague has achieved sales of 2.871 billion yuan, the full year is likely to exceed 4 billion yuan.
, which will be of concern in 2020, has grown in popularity over the past year as the outbreak continued at the beginning of the year.
January 31, people's daily Weibo reported that the Wuhan Virus Institute and the Chinese Academy of Sciences Shanghai drug research team through in-body tests proved that the double yellow link inhibits the role of the new coronavirus, the next step needs to be confirmed by further clinical research.
news has also led to a frenzy of double-yellowing, but the study is only preliminary and has not been clinically proven.
people's discussion of double yellow has been hot for a while.
However, due to being classified as a drug for prevention and control during the outbreak, Mienet forecast data show that in 2020 in China's urban retail pharmacy terminals, including lianhua Qing plague capsules, double yellow even oral liquid for the first time exceeded the 1 billion mark.
In 2020, Avigan, a broad-spectrum antiviral drug developed by Toyama Chemical Industries Co., Ltd. of Japan, was re-entered the public eye and was approved for sale in Japan in March 2014 for the treatment of new and resuscuted influenza.
is also an early contender for the development of new coronavirus drugs.
latest news, Japan's Ministry of Health, Labour and Labor task force on the grounds that "data obtained from the current stage is difficult to clearly determine the effectiveness of the drug" on the grounds of suspension of approval, the results are expected after 2021.
August 2019, The patent for Fabirave's compounds officially expired.
In February 2020, Haizheng Pharmaceuticals' generic Phaviravir tablets( a.g., Fabiravir tablets) were approved for use in the treatment of new or relapsed influenza in adults (only if other anti-flu drug treatments are ineffective or ineffective).
meters of intranet data show that the current Haizheng Pharmaceuticals Fabirawe tablets have achieved part of the international sales, the domestic completion of 19 provinces hanging network, 35 hospitals have completed hospitalization, 20 hospitals completed the bill of lading.
, last year the National Health and Wellness Commission issued eight versions of the new coronary pneumonia treatment program, in which antiviral drugs attracted attention.
The treatment drugs that have entered the diagnosis and treatment program are Lopinavir/Litonavir, Libavelin, chloroquine phosphate, Abidor; immunotherapy drugs have toad monoantigen resistance; medical observation period can be applied drugs have conjugation plague particles, fennel positive gas oral solution, etc.;
December 28, 2020, the National Health Insurance Administration officially issued the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2020).
new version of the health insurance catalogue will be Libawelin injections, Abidor particles and other drugs into the latest version of the national new crown pneumonia diagnosis and treatment program listed drugs have been fully included in the national health insurance directory.
new catalog will be officially launched nationwide from March 1, 2021.
According to Xinhua News Agency, World Health Organization data show that as of 18:44 Central European time on the 19th (Beijing time on the 20th at 1:44), the number of confirmed cases worldwide increased by 312,202 from the previous day to 94124612; 8316 cases, reaching 2034,527, and johns Hopkins University data show that as of 7:22 p.m. Beijing time on the 20th, the number of newly confirmed cases worldwide reached 96058991 and the number of deaths was 2053384.
the United States is the world's worst affected country, with 242,16856 confirmed cases and 401,174 deaths.
the current global new crown epidemic situation is still quite serious, the new crown control drugs for some time is still a necessity, sales will continue to rise.